{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115724","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.877278+00:00","generated_at":"2026-06-22T04:37:00.268550+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nuvectis Pharma reports Q3 net loss $5.9M; provides NXP800/NXP900 clinical updates","bullets":["Net loss $5.9M for Q3 2022 vs $4.7M in Q3 2021; cash $23.6M as of Sep 30, 2022.","Phase 1a dose escalation of NXP800 ongoing; Phase 1b expansion expected to start Q1 2023.","IND-enabling studies for NXP900 ongoing; IND or equivalent submission expected Q1 2023.","Positive preclinical data for NXP800 in ARID1a-mutated gastric cancer model.","Cash runway into H2 2024; formed Scientific Advisory Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115724","json":"https://secwatch.observer/filing/0001104659-22-115724.json","markdown":"https://secwatch.observer/filing/0001104659-22-115724.md","text":"https://secwatch.observer/filing/0001104659-22-115724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465922115724/0001104659-22-115724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465922115724/tm2229896d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:37:00.268550+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"507975e7dd28dd75055df232cc2f49b52c58fbe1","claim":"Nuvectis Pharma, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1875558/000110465922115724/0001104659-22-115724-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}